Clinical Activity Data

Dear Freedom of Information Officer,
I am writing to make a request under the Freedom of Information Act 2000.

Please provide the following information from the financial years 2020/2021 to the end of the financial year 2025/2026:

1) The total number of patients aged under 21 who presented, or were referred within your organisation with a diagnosis or suspected diagnosis of an asbestos-related disease, including but not limited to: mesothelioma, asbestosis, pleural plaques, pleural effusion attributed to asbestos exposure, or diffuse pleural thickening.

2) Please break this figure down by financial year. Where the number of cases in any given year is five or fewer, please state

3) Please confirm whether your organisation holds any coded data for these conditions in patients aged under 21, even if no cases have been recorded during the period.

If you do not hold this information, please confirm that is the case and, where possible, advise which body may hold it.

I am happy to receive this information in any electronic format. If you require clarification to process this request, please contact me at the address below.

Yours faithfully,

Dear Sir/Madam,

I am writing to make a FOI request. Please supply the requested information below:-

1. Please provide, where this information is held in a reportable or centrally recorded format, the number of CAMHS patients under 18 who were prescribed psychotropic medication prior to a formal psychiatric diagnosis being recorded, in each of the last five financial years.
2. Please provide the Trust’s written policy or clinical governance guidance governing circumstances in which CAMHS clinicians may exclude a parent holding parental responsibility from communication about their child’s assessment, treatment or care;
3. Please provide, where this information is held in a reportable or centrally recorded format, the number of CAMHS patients under 18 who were prescribed psychotropic medication following their first CAMHS appointment, in each of the last five financial years.
4. Please provide any Trust policy, guidance, or training material relating to how CAMHS clinicians should proceed where parents holding parental responsibility disagree about treatment decisions;
5. Please provide the average and median number of CAMHS clinical appointments attended by patients before psychotropic medication is first prescribed, for each of the last five financial years;
6. Please provide any Trust policy, guidance, or training materials used within CAMHS which address how clinicians should respond where a parent disagrees with or refuses consent to proposed mental health treatment for a child.
7. Please confirm whether the Trust records within its clinical or administrative systems whether all individuals holding parental responsibility were or are informed or consulted prior to treatment decisions being made for CAMHS patients. If such information is recorded, please confirm the fields or mechanisms used to record this information.

If any part of this request is considered to exceed the cost limit under Section 12 of the Freedom of Information Act 2000, please provide advice and assistance under Section 16 to refine the request so that the information may be supplied.

Yours faithfully,

Dear Gloucestershire Health and Care NHS Foundation Trust,

I am writing under the Freedom of Information Act 2000 to request the following information held by your Trust.

For each of the calendar years 2022, 2023, 2024 and 2025 (to date, if full-year data is not yet available), please provide:

1. The total number of admissions to Specialist Eating Disorder Inpatient Services.
2. The total number of admissions to Intensive Day-Patient Eating Disorder Services.
Where possible, please:

• Provide the data broken down by year.
• Provide a separate figure for patients admitted with a primary diagnosis of Anorexia Nervosa.

If diagnostic breakdowns are recorded using ICD-10 or ICD-11 codes, please include the codes used to define Anorexia Nervosa.

If a breakdown by diagnosis is not readily available within the cost limit, please provide the aggregate totals only.

If the Trust does not hold some or all of this information, please confirm this and direct me to the appropriate body where possible.

I would prefer to receive the information in electronic format (Excel or CSV).

Yours faithfully,

Good evening,

I hope this email finds you well.

Please could I request the following information under the Freedom of Information Act:

1. The number of inpatients in your Trust who died in each year since 2015.
2. The number of these inpatients who were under the age of 18.

Please could you provide this information by email, preferably in a spreadsheet.

If it is not possible to provide the information requested due to the information exceeding the cost of compliance limits identified in Section 12, please provide advice and assistance, under Section 16 obligations of the Act, as to how I can refine my request.

Many thanks and best wishes,

Dear FOI team for Gloucestershire Health and Care NHS Foundation Trust,

Where possible, I would be grateful if the requested data could be provided in an editable format (e.g. .xlsx or .csv). If this is not feasible, a table format would also be acceptable, and example layouts are suggested below for reference.

For all questions, patient numbers should represent unique patients within the specified reporting period. Where a monthly breakdown is not available, please provide unique patient numbers aggregated by quarter instead. If the tables below are not showing correctly due to formatting issues, then please let me know and I can send them in a word document.

Priority questions:

1. The number of patients under the trust’s care with a recorded diagnosis of Dravet syndrome in each month of 2025 (January–December). Patients may be counted in more than one month. Likely coded as ICD-10 code G40.3 or SNOMED code 230437002.
a. Patient numbers segmented by age:
i. <2 years old ii. 2-8 years old iii. 9-17 years old iv. 18 years+ 2. The number of patients under the trust’s care with a recorded diagnosis of Lennox-Gastaut syndrome in each month of 2025 (January-December). Patients may be counted in more than one month. Likely coded as ICD-10 code G40.4 or SNOMED code of 230418006. a. Patient numbers segmented by age: i. <2 years old ii. 2-8 years old iii. 9-17 years old iv. 18 years+ Example table for Q1 & 2: Age/Month Jan-25 Feb-25 Mar-25 Apr-25 May-25 Jun-25 Jul-25 Aug-25 Sep-25 Oct-25 Nov-25 Dec-25 <2 years old 2-8 years old 9-17 years old 18+ years old 3. The number of patients under the trust’s care who have been treated with fenfluramine in 2025 (January-December), separated by month a. Patient numbers segmented by age: i. <2 years old ii. 2-8 years old iii. 9-17 years old iv. 18 years+ b. For these patients, how many of them had a diagnosis of: i. Dravet Syndrome (ICD10 Code: G40.3) SCTID: 230437002 ii. Lennox-Gastaut syndrome (ICD10 Code: G40.4) SCTID: 230418006 Example table for 3 – 12 a)i – b)ii Age group / Month Jan-25 Feb-25 Mar-25 Apr-25 May-25 Jun-25 Jul-25 Aug-25 Sep-25 Oct-25 Nov-25 Dec-25 <2 years Total patients Dravet syndrome Lennox–Gastaut syndrome 2-8 years Total patients Dravet syndrome Lennox–Gastaut syndrome 9-17 years Total patients Dravet syndrome Lennox–Gastaut syndrome 18+ years Total patients Dravet syndrome Lennox–Gastaut syndrome c. For patients with a recorded diagnosis of Dravet syndrome treated with fenfluramine during 2025, please indicate which other anti-seizure medications were recorded for these patients during the year, and the number of patients associated with each medication d. For patients with a recorded diagnosis of Lennox–Gastaut syndrome treated with fenfluramine during 2025, please indicate which other anti-seizure medications were recorded for these patients during the year, and the number of patients associated with each medication. 4. The number of patients under the trust’s care who have been treated with cannabidiol in 2025 (January-December), separated by month a. Patient numbers segmented by age: i. <2 years old ii. 2-8 years old iii. 9-17 years old iv. 18 years+ b. For these patients, how many of them had a diagnosis of: i. Dravet Syndrome (ICD10 Code: G40.3) SCTID: 230437002 ii. Lennox-Gastaut syndrome (ICD10 Code: G40.4) SCTID: 230418006 c. For patients with a recorded diagnosis of Dravet syndrome treated with fenfluramine during 2025, please indicate which other anti-seizure medications were recorded for these patients during the year, and the number of patients associated with each medication d. For patients with a recorded diagnosis of Lennox–Gastaut syndrome treated with fenfluramine during 2025, please indicate which other anti-seizure medications were recorded for these patients during the year, and the number of patients associated with each medication. 5. The number of patients under the trust’s care who have been treated with cenobamate in in 2025 (January-December), separated by month a. Patient numbers segmented by age: i. <2 years old ii. 2-8 years old iii. 9-17 years old iv. 18 years+ b. For these patients, how many of them had a diagnosis of: i. Dravet Syndrome (ICD10 Code: G40.3) SCTID: 230437002 ii. Lennox-Gastaut syndrome (ICD10 Code: G40.4) SCTID: 230418006 c. For patients with a recorded diagnosis of Dravet syndrome treated with fenfluramine during 2025, please indicate which other anti-seizure medications were recorded for these patients during the year, and the number of patients associated with each medication d. For patients with a recorded diagnosis of Lennox–Gastaut syndrome treated with fenfluramine during 2025, please indicate which other anti-seizure medications were recorded for these patients during the year, and the number of patients associated with each medication. 6. The number of patients under the trust’s care who have been treated with rufinamide in 2025 (January-December), separated by month a. Patient numbers segmented by age: i. <2 years old ii. 2-8 years old iii. 9-17 years old iv. 18 years+ b. For these patients, how many of them had a diagnosis of: i. Lennox-Gastaut syndrome (ICD10 Code: G40.4) SCTID: 230418006 c. For patients with a recorded diagnosis of Lennox–Gastaut syndrome treated with fenfluramine during 2025, please indicate which other anti-seizure medications were recorded for these patients during the year, and the number of patients associated with each medication. 7. The number of patients under the trust’s care who have been treated with stiripentol in 2025 (January-December), separated by month a. Patient numbers segmented by age: i. <2 years old ii. 2-8 years old iii. 9-17 years old iv. 18 years+ b. For these patients, how many of them had a diagnosis of: i. Dravet Syndrome (ICD10 Code: G40.3) SCTID: 230437002 ii. Lennox-Gastaut syndrome (ICD10 Code: G40.4) SCTID: 230418006 c. For patients with a recorded diagnosis of Dravet syndrome treated with fenfluramine during 2025, please indicate which other anti-seizure medications were recorded for these patients during the year, and the number of patients associated with each medication d. For patients with a recorded diagnosis of Lennox–Gastaut syndrome treated with fenfluramine during 2025, please indicate which other anti-seizure medications were recorded for these patients during the year, and the number of patients associated with each medication. Good to know questions: 8. The number of patients under the trust’s care who have been treated with clobazam in 2025 (January-December), separated by month a. Patient numbers segmented by age: i. <2 years old ii. 2-8 years old iii. 9-17 years old iv. 18 years+ b. For these patients, how many of them had a diagnosis of: i. Dravet Syndrome (ICD10 Code: G40.3) SCTID: 230437002 ii. Lennox-Gastaut syndrome (ICD10 Code: G40.4) SCTID: 230418006 c. For patients with a recorded diagnosis of Dravet syndrome treated with fenfluramine during 2025, please indicate which other anti-seizure medications were recorded for these patients during the year, and the number of patients associated with each medication d. For patients with a recorded diagnosis of Lennox–Gastaut syndrome treated with fenfluramine during 2025, please indicate which other anti-seizure medications were recorded for these patients during the year, and the number of patients associated with each medication. 9. The number of patients under the trust’s care who have been treated with sodium valproate in 2025 (January-December), separated by month a. Patient numbers segmented by age: i. <2 years old ii. 2-8 years old iii. 9-17 years old iv. 18 years+ b. For these patients, how many of them had a diagnosis of: i. Dravet Syndrome (ICD10 Code: G40.3) SCTID: 230437002 ii. Lennox-Gastaut syndrome (ICD10 Code: G40.4) SCTID: 230418006 c. For patients with a recorded diagnosis of Dravet syndrome treated with fenfluramine during 2025, please indicate which other anti-seizure medications were recorded for these patients during the year, and the number of patients associated with each medication d. For patients with a recorded diagnosis of Lennox–Gastaut syndrome treated with fenfluramine during 2025, please indicate which other anti-seizure medications were recorded for these patients during the year, and the number of patients associated with each medication. 10. The number of patients under the trust’s care who have been treated with topiramate in 2025 (January-December), separated by month a. Patient numbers segmented by age: i. <2 years old ii. 2-8 years old iii. 9-17 years old iv. 18 years+ b. For these patients, how many of them had a diagnosis of: i. Dravet Syndrome (ICD10 Code: G40.3) SCTID: 230437002 ii. Lennox-Gastaut syndrome (ICD10 Code: G40.4) SCTID: 230418006 c. For patients with a recorded diagnosis of Dravet syndrome treated with fenfluramine during 2025, please indicate which other anti-seizure medications were recorded for these patients during the year, and the number of patients associated with each medication d. For patients with a recorded diagnosis of Lennox–Gastaut syndrome treated with fenfluramine during 2025, please indicate which other anti-seizure medications were recorded for these patients during the year, and the number of patients associated with each medication. 11. The number of patients under the trust’s care who have been treated with lamotrigine in 2025 (January-December), separated by month a. Patient numbers segmented by age: i. <2 years old ii. 2-8 years old iii. 9-17 years old iv. 18 years+ b. For these patients, how many of them had a diagnosis of: i. Lennox-Gastaut syndrome (ICD10 Code: G40.4) SCTID: 230418006 c. For patients with a recorded diagnosis of Lennox–Gastaut syndrome treated with fenfluramine during 2025, please indicate which other anti-seizure medications were recorded for these patients during the year, and the number of patients associated with each medication. Many thanks,

Dear Sir or Madam,

I am writing to make a request under the Freedom of Information act

I am seeking hospital-level activity data within your health authority, as outlined below.

Dataset 1: ICD-10 Diagnosis Data

For each hospital, please provide:
• From 2022 up to the latest data available, preferably by calendar year
• Primary (first) diagnosis ICD-10 codes (three or more characters), chapters A–Q only, including patients outsourced to the private sector
• Number of cases per ICD-10 code
• Hospital name and postcode

Dataset 2: Procedures / Surgery Data

For each hospital, please provide:
• Years: 2020 up to and including 2024, preferably by calendar year
• Primary procedure OPCS codes, all chapters, including patients outsourced to the private sector
• Number of cases per OPCS code
• Hospital name and postcode

With regard to case numbers for both ICD-10 and OPCS data, we recognise that disclosure controls may apply where case numbers are fewer than five. In such instances, please indicate the value as “<5” or similar format, depending on your small-case policy. We would be grateful if the data could be provided in a machine-readable format (for example, CSV or Excel), if possible. For context, we already hold comparable datasets for most European countries. This information is collected and processed for research and pharmaceutical organisations, where it is used for market analysis and clinical trial planning. We hope this explains the purpose and potential value of supplying the requested data. Please let us know if any clarification is required. I look forward to hearing from you.

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), Neuropathy, and Guillain-Barré Syndrome (GBS) – 2015–Present

I am asking whether your Trust holds any activity data relating to patients who already have these diagnoses, including:

– community nursing contacts
– community therapy or rehabilitation contacts
– community outpatient episodes
– community inpatient episodes
– any other activity recorded under these conditions (if applicable)

If your Trust does not hold any activity data for patients with these conditions, please confirm this explicitly.

I write to request the following information:

1. Does your Trust currently provide or commission acupuncture treatments or acupuncture services?

2. For each of the last five fiscal years (2020/2021, 2021/2022, 2022/23, 2023/24, 2024/25), please provide:
a. The amount spent on the provision or commissioning of acupuncture services or treatments
b. The number of patients seen by these services

Year Amount Spent Number of patients
2020/21
2021/22
2022/23
2023/24
2024/25

3. Do you currently have a contract in place with any provider for the provision of acupuncture services? If so, please provide a copy of the contract.

4. Which external organisations, charities or companies (eg the Sam Buxton Sunflower Healing Trust) have you contracted or engaged with over the provision of acupuncture services in the five fiscal years? Please include copies of any promotional materials, advertising materials or other documentation provided by the external organisation as part of this engagement

Please interpret my request in the broadest possible terms. If you have any doubt as to whether any information falls within the scope of my request, please assume that it does and include it in your response.

Yours sincerely

I am writing to request the following information under the Freedom of Information Act 2000:
For your adult eating disorder service from January 2025-November 2025 what were the BMI of inpatients and community patients with an eating disorder at the time they were discharged?

For your adult eating disorderservice in 2025 how many inpatients and communitypatients with an eating disorderwere discharged with a BMI ofunder 15?

For your Children’s eating disorder service what was the weight for height percentage of inpatientsand community patients with an eating disorder at the time they were discharged between January 2025 and November 2025?

For your Children’s eating disorder service in 2025 how many inpatients and community patients with an eating disorderwere discharged at a weight for height of less than 75 ?

At point of discharge if patientshad a BMI of under 15, or equivalent to weight for height ofless than 75, where were yourpatients discharged to between January 2025 and November 2025? (for both adults and children)

In your adult and children’s eatingdisorder service what treatment is offered to inpatient andcommunity patients who had a BMI of under 15, or equivalent to weight for height of less than 75 between January 2025 and November 2025?